Department of Molecular Medicine, "Sapienza" University of Rome, viale Regina Elena 291, 00161 Rome, Italy.
Biomater Sci. 2017 Aug 22;5(9):1884-1888. doi: 10.1039/c7bm00387k.
Driven by the promises of gene therapy, PEGylated cationic liposomes (CLs) have been investigated for decades, but their use in the clinical setting is far from established. Such a dichotomy is due to several factors that have been ignored over the last two decades. The hardest challenge seems to occur when PEGylated CLs come into contact with a physiological environment (e.g. the blood). Recent evidence has demonstrated that PEGylation does not completely prevent protein binding (as believed so far), but a biomolecular shell, termed "biomolecular corona" (BC), covers the liposome surface. Here we show that the formation of a BC not only affects the surface properties of PEGylated CLs, but also, and significantly, their bilayer structure thus impairing their ability to safely deliver their cargo to the target site. Therefore, a mechanistic understanding of the structures emerging from liposome-protein interactions may represent a truly new paradigm for the clinical translation of PEGylated CLs.
受基因治疗的承诺推动,聚乙二醇化阳离子脂质体 (CL) 已被研究了数十年,但它们在临床环境中的应用还远未得到确立。造成这种明显差异的原因有几个,而在过去二十年中,这些因素一直被忽视。聚乙二醇化 CL 与生理环境(例如血液)接触时似乎面临着最大的挑战。最近的证据表明,聚乙二醇化并不能像目前认为的那样完全阻止蛋白质结合,而是形成了一种称为“生物分子冠” (BC) 的生物分子外壳,覆盖在脂质体表面。我们的研究表明,BC 的形成不仅会影响聚乙二醇化 CL 的表面特性,而且还会显著影响其双层结构,从而损害其将有效载荷安全递送至靶部位的能力。因此,对脂质体-蛋白质相互作用所产生的结构的机制理解可能为聚乙二醇化 CL 的临床转化带来真正的新范例。